Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | KTN0073-IgG2 |
Synonyms | |
Therapy Description |
KTN0073-IgG2 is a MET targeted antibody engineered to an IgG2 isotype, which inhibits ligand binding and induces degradation of both wild-type and mutant forms of MET, resulting in decreased tumor cell proliferation, including tumor cells harboring MET mutations and/or amplification (PMID: 27550450). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KTN0073-IgG2 | MET Antibody 28 MET Inhibitor 59 | KTN0073-IgG2 is a MET targeted antibody engineered to an IgG2 isotype, which inhibits ligand binding and induces degradation of both wild-type and mutant forms of MET, resulting in decreased tumor cell proliferation, including tumor cells harboring MET mutations and/or amplification (PMID: 27550450). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|